Comparative Pharmacology
Head-to-head clinical analysis: ACTIDIL versus HISTAFED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTIDIL versus HISTAFED.
ACTIDIL vs HISTAFED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
H1-receptor antagonist; competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, blocking histamine-induced bronchoconstriction, vasodilation, and increased capillary permeability.
HISTAFED is a combination of pseudoephedrine, a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the nasal mucosa causing vasoconstriction, and triprolidine, a first-generation antihistamine that competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, thereby preventing histamine-mediated effects.
2.5 mg orally every 4 to 6 hours as needed; maximum 10 mg per day.
60 mg orally every 4 to 6 hours as needed; maximum 360 mg per day.
None Documented
None Documented
Terminal elimination half-life is approximately 20-25 hours in healthy adults; may be prolonged in elderly or patients with hepatic impairment.
3-4 hours for pseudoephedrine component; shorter in children (2-3 h), prolonged in renal impairment
Renal excretion of unchanged drug and metabolites accounts for approximately 60-80% of the administered dose; biliary/fecal elimination comprises the remainder (20-40%).
Renal (approximately 65% as unchanged drug and metabolites), biliary/fecal (35%)
Category C
Category C
Antihistamine
Antihistamine/Decongestant Combination